6Adams J,Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib)[J]. Cancer Invest, 2004, 22:304-311.
7Jagannath S,Durie B,Wolf J,et al.Bortezomib therapy alone and in eombination with dexamethasone for previously untreated symptomatie multiple myeloma[J]. Br J Haematol,2005, 129(6):776-783.
8Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma Committee of theEBMT European Group for Blood and Marrow Transplant[J]. Br J Haematol, 1998, 102:1115-1231.
9Mateos MV,Hernandez JM.Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multieenter phase Ⅰ/Ⅱ study [J].Blood, 2006, Jun 13 [Epub ahead of print].
10Oakervee HE,Popat R. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma [J]. Br J Haematol, 2005, 129(6):755-762.
1Moore H, Romeril K. Multiple myeloma presenting with a fever of un- known origin and development of thrombotic thrombocytopenic purpura post- bortezomib[J].InternMed J, 2011,41 (4) : 348 - 350.
